PT  - JOURNAL ARTICLE
AU  - Dana Cramariuc
AU  - Barbara Patricia Rogge
AU  - Mai Tone Lønnebakken
AU  - Kurt Boman
AU  - Edda Bahlmann
AU  - Christa Gohlke-Bärwolf
AU  - John B Chambers
AU  - Terje R Pedersen
AU  - Eva Gerdts
TI  - Sex differences in cardiovascular outcome during progression of aortic valve stenosis
AID  - 10.1136/heartjnl-2014-306078
DP  - 2015 Feb 01
TA  - Heart
PG  - 209--214
VI  - 101
IP  - 3
4099  - http://heart.bmj.com/content/101/3/209.short
4100  - http://heart.bmj.com/content/101/3/209.full
SO  - Heart2015 Feb 01; 101
AB  - Objective Women with severe aortic valve stenosis (AS) have better LV systolic function and more concentric LV geometry than their male counterparts. However, sex differences in cardiovascular (CV) outcome during progression of AS have not been reported from a longitudinal prospective study.Methods Doppler echocardiography and CV events were recorded during a median of 4.0 years in 979 men and 632 women aged 28–86 (mean 67±10) years in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study. LV systolic function was assessed by EF and midwall shortening (MWS). Study outcomes were AS-related events, ischaemic CV events and total mortality.Results The annular cumulative incidence of AS events, ischaemic CV events and death was 8.1%, 3.4% and 2.8% in women, and 8.9%, 4.4% and 2.4% in men, respectively. Women and men had similar AS progression rate whether measured by peak jet velocity, mean gradient or valve area. In multivariate analyses, female sex independently predicted less reduction in LV MWS and EF during follow-up (both p<0.05). In time-varying Cox analyses, women had a 40% lower rate of ischaemic CV events (95% CI 21% to 54%), in particular, more than 50% lower rate of stroke and coronary artery bypass grafting, and a 31% lower all-cause mortality (95% CI 1% to 51%), independent of active study treatment, age and hypertension, as well as time-varying valve area, low systolic function and abnormal LV geometry. AS event rate did not differ by sex.Conclusions In the SEAS study, women and men had similar rates of AS progression and AS-related events. However, women had lower total mortality and ischaemic CV event rate than men independent of confounders.Trial registration number ClinicalTrials.gov identifier: NCT00092677.